Abstract

Cen Zhang*, Dongsheng Li, Man Qiao

Objectives: The aim of this study was to evaluate the clinical characteristics of Community-Acquired Pneumonia (CAP) patients with infected Trichosporon asahii in urinary tract. Methods: Patients diagnosed with Trichosporon asahii isolated from the patients with urinary tract infection between January 2015 and November 2019, were retrospectively reviewed in this study. Clinical data were collected for each patient, including age, gender, co-morbid diseases, relevant tests, antimicrobial susceptibility test and impact on patient’s antifungal drugs, etc. Results: Ten patients (9 males and 1 female; range of age: 63-91, and average age of 80.1) were enrolled into this study. Of the ten patients, ten patients had old cerebral infarction, ten patient had coronary heart disease, five patient had hypertension, three patient had diabetes, three patient had gastrointestinal bleeding, one patient had lung cancer. Of the ten enrolled patients, all patients were suffering from cough and sputum, and five patients were presented with fever. However, there were no urinary tract symptoms such as frequent urination, urgency and pain. No complications occurred. Furthermore, all patients had increased C-reactive Protein (CRP), only three patients had increased White Blood Cell (WBC). At the same time, nine had decreased albumin (ALB), seven had percentage of Eosinophils (EO%),and five had helper T lymphocytes (CD4). All patients were treated with anti-infection, and expectorant. Among antifungal drugs, amphotericin and voriconazole have higher sensitive rate. Finally, five patients were discharged with a better health condition, two patients were automatically discharged, and three patients were died. The average follow-up for patients was 3 months, three patients were died. Conclusion: The results suggested that the mortality rate of Trichosporon asahii pneumonia is very high; there - fore, patients with infected Trichosporon asahii should be more actively treated by antifungal drug such as voriconazole.